Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azithromycin + Hydroxychloroquine in Severe COVID-19 (Coalition II)
NCT04321278Phase 3Completed
- Sponsor
- Hospital Israelita Albert Einstein
- Start
- Mar 2020
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of azithromycin in COVID-19 pneumonia (2 arms), sponsored by Hospital Israelita Albert Einstein. Primary endpoint: Clinical status on a 6-point ordinal scale at 15 days. Started Mar 2020; status: completed.
02
Drugs
azithromycin
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04321278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04321278.